Evidence map›Paper›PMID 38773214›Full record

ArticleScientific reports2024

Uracil as a biomarker for spatial pyrimidine metabolism in the development of gingivobuccal oral squamous cell carcinoma.

Soni Shaikh, Sangramjit Basu, Swarnendu Bag, Ankita Chatterjee, Sourav Datta, Devmalya Banerjee, Kapila Manikantan, Indu Arun, Pattatheyil Arun, Nidhan K Biswas and 5 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Targeted metabolomic profiling of gastric cancer biopsies.The Indian journal of medical research · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Soni ShaikhTata Medical Center, 14 MAR (E-W), New Town, Rajarhat, Kolkata, WB, 700160, India.
Sangramjit Basu *Tata Translational Cancer Research Centre (TTCRC), 14 MAR (E-W), New Town, Rajarhat, Kolkata, WB, 700160, India.
Swarnendu Bag *Tata Medical Center, 14 MAR (E-W), New Town, Rajarhat, Kolkata, WB, 700160, India.
Ankita ChatterjeeNational Institute of Biomedical Genomics, P.O.: N.S.S., Kalyani, WB, 741251, India.
Sourav DattaNarayana Superspeciality Hospital, 120, 1, Andul Rd, Shibpur, Howrah, WB, 711103, India.
Devmalya BanerjeeNarayana Superspeciality Hospital, 120, 1, Andul Rd, Shibpur, Howrah, WB, 711103, India.
Kapila ManikantanTata Medical Center, 14 MAR (E-W), New Town, Rajarhat, Kolkata, WB, 700160, India.
Indu ArunTata Medical Center, 14 MAR (E-W), New Town, Rajarhat, Kolkata, WB, 700160, India.
Pattatheyil ArunTata Medical Center, 14 MAR (E-W), New Town, Rajarhat, Kolkata, WB, 700160, India.
Nidhan K BiswasNational Institute of Biomedical Genomics, P.O.: N.S.S., Kalyani, WB, 741251, India.
Arindam MaitraNational Institute of Biomedical Genomics, P.O.: N.S.S., Kalyani, WB, 741251, India.
Deepak Kumar MishraTata Medical Center, 14 MAR (E-W), New Town, Rajarhat, Kolkata, WB, 700160, India.
Partha P MajumderNational Institute of Biomedical Genomics, P.O.: N.S.S., Kalyani, WB, 741251, India.
Harsh DharNarayana Superspeciality Hospital, 120, 1, Andul Rd, Shibpur, Howrah, WB, 711103, India. harsh.dhar@medicasynergie.in.
Geetashree MukherjeeTata Medical Center, 14 MAR (E-W), New Town, Rajarhat, Kolkata, WB, 700160, India. geetashree.mukherjee@tmckolkata.com.

Funding

Department of Biotechnology, Ministry of Science and Technology, India No./BT/Med-II/NIBMG/SyMeC/2014/Vol II).
6 · The paper itself

Abstract

No biomarker has yet been identified that allows accurate diagnosis and prognosis of oral cancers. In this study, we investigated the presence of key metabolites in oral cancer using proton nuclear magnetic resonance (NMR) spectroscopy to identify metabolic biomarkers of gingivobuccal oral squamous cell carcinoma (GB-OSCC). NMR spectroscopy revealed that uracil was expressed in 83.09% of tumor tissues and pyrimidine metabolism was active in GB-OSCC; these results correlated well with immunohistochemistry (IHC) and RNA sequencing data. Based on further gene and protein analyses, we proposed a pathway for the production of uracil in GB-OSCC tissues. Uridinetriphosphate (UTP) is hydrolyzed to uridine diphosphate (UDP) by CD39 in the tumor microenvironment (TME). We hypothesized that UDP enters the cell with the help of the UDP-specific P2Y6 receptor for further processing by ENTPD4/5 to produce uracil. As the ATP reserves diminish, the weakened immune cells in the TME utilize pyrimidine metabolism as fuel for antitumor activity, and the same mechanism is hijacked by the tumor cells to promote their survival. Correspondingly, the differential expression of ENTPD4 and ENTPD5 in immune and tumor cells, respectively, indicatedtheir involvement in disease progression. Furthermore, higher uracil levels were detected in patients with lymph node metastasis, indicating that metastatic potential is increased in the presence of uracil. The presence of uracil and/or expression patterns of intermediate molecules in purine and pyrimidine pathways, such asCD39, CD73, and P2Y6 receptors together with ENTPD4 and ENTPD5, hold promise as biomarker(s) for oral cancer diagnosis and prognosis.

Indexed as

Biomarkers, TumorMouth NeoplasmsPyrimidinesUracilAgedApyraseCarcinoma, Squamous CellFemaleHumansMaleMiddle AgedTumor MicroenvironmentApyraseBiomarkers, TumorpyrimidinePyrimidinesUracilGB-OSCCNuclear magnetic resonanceP2Y6receptorTumor microenvironmentUracil

Identifiers

PMID38773214
PMCPMC11109148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.